Genetic variation of circHIBADH enhances prostate cancer risk through regulating HNRNPA1-related RNA splicing

Abstract

The current study aimed to investigate associations of circRNAs and related genetic variants with the risk of prostate cancer (PCa) as well as to elucidate biological mechanisms underlying the associations. We first compared expression levels of circRNAs between 25 paired PCa and adjacent normal tissues to identify risk-associated circRNAs by using the MiOncoCirc database. We then used logistic regression models to evaluate associations between genetic variants in candidate circRNAs and PCa risk among 4662 prostate cancer patients and 3114 healthy controls, and identified circHIBADH rs11973492 T>C as a significant risk-associated variant (odds ratio = 1.20, 95% confidence interval: 1.08-1.34, P = 7.06 × 10⁻⁴) in a dominant genetic model, which altered the secondary structure of the corresponding RNA chain. In the in silico analysis, we found that circHIBADH sponged and silenced 21 RNA-binding proteins (RBPs) enriched in the RNA splicing pathway, among which HNRNPA1 was identified and validated as a hub RBP using an external RNA-sequencing data as well as the in-house (four tissue samples) and publicly available single-cell transcriptomes. Additionally, we demonstrated that HNRNPA1 influenced hallmarks including MYC target, DNA repair, and E2F target signaling pathways, thereby promoting carcinogenesis. In conclusion, genetic variants in circHIBADH may act as sponges and inhibitors of RNA splicing-associated RBPs including HNRNPA1, playing an oncogenic role in PCa.

Keywords

genetic variants / prostate cancer / circRNA / RNA-binding protein / RNA splicing / sing-cell RNA sequencing

Fundings

This work was supported by the Medical Research Project of Jiangsu Commission of Health (Grant No. M2022015).

Acknowledgments

We thank Dr. Mulong Du from Nanjing Medical University for his guidance in the data interpretation.

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660

[2] Wang YA, Sfakianos J, Tewari AK, et al. Molecular tracing of prostate cancer lethality[J]. Oncogene, 2020, 39(50): 7225-7238. doi: 10.1038/s41388-020-01496-5

[3] Komura K, Sweeney CJ, Inamoto T, et al. Current treatment strategies for advanced prostate cancer[J]. Int J Urol, 2018, 25(3): 220-231. doi: 10.1111/iju.13512

[4] Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability of cancer among twins in Nordic countries[J]. JAMA, 2016, 315(1): 68-76. doi: 10.1001/jama.2015.17703

[5] Conti DV, Darst BF, Moss LC, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction[J]. Nat Genet, 2021, 53(1): 65-75. doi: 10.1038/s41588-020-00748-0

[6] Welter D, MacArthur J, Morales J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations[J]. Nucleic Acids Res, 2014, 42(D1): D1001-D1006. doi: 10.1093/nar/gkt1229

[7] Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs[J]. Nat Rev Genet, 2019, 20(11): 675-691. doi: 10.1038/s41576-019-0158-7

[8] Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs[J]. Nat Commun, 2016, 7: 11215. doi: 10.1038/ncomms11215

[9] Xia P, Wang S, Ye B, et al. A circular RNA protects dormant hematopoietic stem cells from DNA Sensor cGAS-mediated exhaustion[J]. Immunity, 2018, 48(4): 688-701.e7. doi: 10.1016/j.immuni.2018.03.016

[10] Du WW, Fang L, Yang W, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity[J]. Cell Death Differ, 2017, 24(2): 357-370. doi: 10.1038/cdd.2016.133

[11] Chen N, Zhao G, Yan X, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1[J]. Genome Biol, 2018, 19(1): 218. doi: 10.1186/s13059-018-1594-y

[12] Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus[J]. Nat Struct Mol Biol, 2015, 22(3): 256-264. doi: 10.1038/nsmb.2959

[13] Zhang M, Zhao K, Xu X, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma[J]. Nat Commun, 2018, 9(1): 4475. doi: 10.1038/s41467-018-06862-2

[14] Bi J, Liu H, Dong W, et al. Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence[J]. Mol Cancer, 2019, 18(1): 133. doi: 10.1186/s12943-019-1060-9

[15] Liu T, Liu S, Xu Y, et al. Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric cancer by sponging miR-130a/miR-107 and modulating PTEN[J]. Cancer Res Treat, 2018, 50(4): 1396-1417. doi: 10.4143/crt.2017.537

[16] Kleivi Sahlberg K, Bottai G, Naume B, et al. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients[J]. Clin Cancer Res, 2015, 21(5): 1207-1214. doi: 10.1158/1078-0432.CCR-14-2011

[17] Chen S, Huang V, Xu X, et al. Widespread and functional RNA circularization in localized prostate cancer[J]. Cell, 2019, 176(4): 831-843. e22. doi: 10.1016/j.cell.2019.01.025

[18] Shen Z, Zhou L, Zhang C, et al. Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel[J]. Cancer Lett, 2020, 468: 88-101. doi: 10.1016/j.canlet.2019.10.006

[19] Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer[J]. Cell, 2019, 176(4): 869-881. e13. doi: 10.1016/j.cell.2018.12.021

[20] Cheng Y, Meng Y, Li S, et al. Genetic variants in the cholesterol biosynthesis pathway genes and risk of prostate cancer[J]. Gene, 2021, 774: 145432. doi: 10.1016/j.gene.2021.145432

[21] Tuong ZK, Loudon KW, Berry B, et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer[J]. Cell Rep, 2021, 37(12): 110132. doi: 10.1016/j.celrep.2021.110132

[22] Henry GH, Malewska A, Joseph DB, et al. A cellular anatomy of the normal adult human prostate and prostatic urethra[J]. Cell Rep, 2018, 25(12): 3530-3542. e5. doi: 10.1016/j.celrep.2018.11.086

[23] Yang Q, Li F, He AT, et al. Circular RNAs: expression, localization, and therapeutic potentials[J]. Mol Ther, 2021, 29(5): 1683-1702. doi: 10.1016/j.ymthe.2021.01.018

[24] Yu Y, Lv D, Wang C, et al. Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p[J]. Mol Cancer, 2022, 21(1): 12. doi: 10.1186/s12943-021-01480-x

[25] Ding L, Zheng Q, Lin Y, et al. Exosome-derived circTFDP2 promotes prostate cancer progression by preventing PARP1 from caspase-3-dependent cleavage[J]. Clin Transl Med, 2023, 13(1): e1156. doi: 10.1002/ctm2.1156

[26] Zhou R, Wu Y, Wang W, et al. Circular RNAs (circRNAs) in cancer[J]. Cancer Lett, 2018, 425: 134-142. doi: 10.1016/j.canlet.2018.03.035

[27] Conn SJ, Pillman KA, Toubia J, et al. The RNA binding protein quaking regulates formation of circRNAs[J]. Cell, 2015, 160(6): 1125-1134. doi: 10.1016/j.cell.2015.02.014

[28] Ashwal-Fluss R, Meyer M, Pamudurti NR, et al. circRNA biogenesis competes with pre-mRNA splicing[J]. Mol Cell, 2014, 56(1): 55-66. doi: 10.1016/j.molcel.2014.08.019

[29] Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production[J]. Genes Dev, 2014, 28(20): 2233-2247. doi: 10.1101/gad.251926.114

[30] Zhang X, Wang H, Zhang Y, et al. Complementary sequence-mediated exon circularization[J]. Cell, 2014, 159(1): 134-147. doi: 10.1016/j.cell.2014.09.001

[31] Paschalis A, Sharp A, Welti JC, et al. Alternative splicing in prostate cancer[J]. Nat Rev Clin Oncol, 2018, 15(11): 663-675. doi: 10.1038/s41571-018-0085-0

[32] Kawamura N, Nimura K, Saga K, et al. SF3B2-mediated RNA splicing drives human prostate cancer progression[J]. Cancer Res, 2019, 79(20): 5204-5217. doi: 10.1158/0008-5472.CAN-18-3965

[33] Roy R, Huang Y, Seckl MJ, et al. Emerging roles of hnRNPA1 in modulating malignant transformation[J]. WIREs RNA, 2017, 8(6): e1431. doi: 10.1002/wrna.1431

[34] Tummala R, Lou W, Gao AC, et al. Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells[J]. Mol Cancer Ther, 2017, 16(12): 2770-2779. doi: 10.1158/1535-7163.MCT-17-0030

[35] Zhang M, Sun Y, Huang C, et al. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression[J]. Cell Death Dis, 2021, 12(10): 855. doi: 10.1038/s41419-021-03966-4

[36] Lian C, Zhang C, Tian P, et al. Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity[EB/OL]. [2023-11-28]. http://dx.doi.org/10.1101/2023.11.28.569112.

[37] Möller K, Wecker AL, Höflmayer D, et al. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2: ERG fusion-negative prostate cancers[J]. Virchows Arch, 2020, 477(5): 625-636. doi: 10.1007/s00428-020-02834-4

[38] Kristensen LS, Jakobsen T, Hager H, et al. The emerging roles of circRNAs in cancer and oncology[J]. Nat Rev Clin Oncol, 2022, 19(3): 188-206. doi: 10.1038/s41571-021-00585-y